Please use this identifier to cite or link to this item:
Type
ArticleCopyright
Open access
Collections
- INI - Artigos de Periódicos [3463]
- IOC - Artigos de Periódicos [12656]
Metadata
Show full item record
REACTIVATION OF CUTANEOUS AND MUCOCUTANEOUS TEGUMENTARY LEISHMANIASIS IN RHEUMATOID ARTHRITIS PATIENTS: AN EMERGING PROBLEM?
Artrite Reumatóide
Reativação
Fatores de Necrose Tumoral
Metotrexato
Author
Affilliation
Abstract
Rheumatoid arthritis (RA) is a chronic condition that is frequent in patients living in tropical areas exposed to leishmaniasis. RA therapy involves immunosuppressant drugs such as methotrexate (MTX), monoclonal antibodies (mAbs) and prednisone. We report an unusual presentation of cutaneous (CL) or mucocutaneous leishmaniasis (ML) in RA patients from an endemic area of leishmaniasis. A 51-year-old woman noted a cutaneous ulcer on her left ankle during MTX and prednisone RA therapy. Initially diagnosed as a venous stasis ulcer, the aspirate of the injury revealed the presence of Leishmania DNA. A 73-year-old woman presenting non-ulcerated, infiltrated and painful erythematous nodules inside her nostrils while receiving MTX, anti-TNF mAb, and prednisone for RA, had also the aspirate of injuries showing the presence of Leishmania DNA. Both patients healed after the therapy with liposomal amphotericin. The RA therapy has changed to low-dose prednisone, without further reactivation episodes. Both cases suggest that CL or ML can reactivate after administration of an immunosuppressant for RA treatment. Therefore, immunosuppressive treatments for RA should be carefully prescribed in patients from endemic areas or with a history of CL and ML.
Keywords in Portuguese
LeishmanioseArtrite Reumatóide
Reativação
Fatores de Necrose Tumoral
Metotrexato
Share